This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chiodini, I. Articles by Scillitani, A. Search for Related Content PubMed PubMed Citation Articles by Chiodini, I. Articles by Scillitani, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB HYDROCORTISONE

Bone Loss Rate in Adrenal Incidentalomas: A Longitudinal Study

Clinical and Research Unit of Endocrinology (I.C., M.T., V.T., A.S.), Unit of Internal Medicine (V.C.), and Department of Radiology (G.G., M.C.), Scientific Institute Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Foggia, Italy; and Unit of Endocrinology, San Giuseppe-Fatebenefratelli A.Fa.R. Hospital (I.C.), Milan, Italy

Address all correspondence and requests for reprints to: Alfredo Scillitani, M.D., Clinical and Research Unit of Endocrinology, Scientific Institute Casa Sollievo della Sofferenza, Viale Cappuccini, 71013 San Giovanni Rotondo, Foggia, Italy. E-mail: endocrinologia{at}operapadrepio.it

Abstract

Although by definition patients with adrenal incidentalomas (AI) do not have evident clinical syndromes, they may frequently suffer from subclinical hypercortisolism (SH). This is of some importance because of evidence that SH may lead to clinical complications, including bone loss. Thus, the understanding of bone involvement due to SH may be extremely important in the management of AI. Unfortunately, the available data on bone mineral density (BMD) in AI patients come from cross-sectional studies, which, to further complicate our understanding, are also conflicting, probably due to a different selection of patients and/or the variability in cortisol secretion (CS) often described in AI. To gain further insight about this topic, we performed a longitudinal study evaluating the rate of spinal and femoral bone loss levels in 24 females with AI.

AI subjects were subdivided in two groups on the basis of the median of urinary cortisol secretion (UFC): group I (n = 12; UFC, <140.4 nmol/24 h) and group II (n = 12; UFC, >140.4 nmol/24 h). Spinal BMD was measured by both single energy quantitative computed tomography (L1–L4) and dual energy x-ray absorptiometry (DXA; L2–L4), and femoral BMD was determined by DXA. Bone loss rate was expressed as the change in z-score per yr.

The spinal bone loss rate was higher (P < 0.005) in group II than in group I when measured by both quantitative computed tomography (-0.19 ± 0.14 vs. 0.00 ± 0.15) and DXA (-0.19 ± 0.17 vs. 0.00 ± 0.11). Moreover, CS and spinal bone loss rate were significantly correlated when patients were considered together.

In conclusion, our data show that 1) AI patients with higher CS have increased lumbar trabecular bone loss rate than those with lower CS; and 2) the degree of spinal bone loss rate is related to the degree of CS. Thus, lumbar spine (LS) BMD has to be evaluated for well balanced decision-making on the treatment of choice for AI female patients.

This article has been cited by other articles:

				I. Chiodini, M. L. Mascia, S. Muscarella, C. Battista, S. Minisola, M. Arosio, S. A. Santini, G. Guglielmi, V. Carnevale, and A. Scillitani Subclinical Hypercortisolism among Outpatients Referred for Osteoporosis Ann Intern Med, October 16, 2007; 147(8): 541 - 548. [Abstract] [Full Text] [PDF]

				I. Chiodini, G. Guglielmi, C. Battista, V. Carnevale, M. Torlontano, M. Cammisa, V. Trischitta, and A. Scillitani Spinal Volumetric Bone Mineral Density and Vertebral Fractures in Female Patients with Adrenal Incidentalomas: The Effects of Subclinical Hypercortisolism and Gonadal Status J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2237 - 2241. [Abstract] [Full Text] [PDF]

				G. Mansmann, J. Lau, E. Balk, M. Rothberg, Y. Miyachi, and S. R. Bornstein The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management Endocr. Rev., April 1, 2004; 25(2): 309 - 340. [Abstract] [Full Text] [PDF]

				G. D. Braunstein and for the National Institutes of Health State-of-the Management of the Clinically Inapparent Adrenal Mass Ann Intern Med, March 2, 2004; 140(5): 401 - 402. [Full Text] [PDF]

				I. Chiodini, L. Tauchmanova, M. Torlontano, C. Battista, G. Guglielmi, M. Cammisa, A. Colao, V. Carnevale, R. Rossi, S. Di Lembo, et al. Bone Involvement in Eugonadal Male Patients with Adrenal Incidentaloma and Subclinical Hypercortisolism J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5491 - 5494. [Abstract] [Full Text] [PDF]